promet consortium

In close collaboration of basic scientists with clinical researchers the pathways of minimal residual disease will be explored using functional genomics and expression profiling as technology platforms, advanced experimental models of minimal residual disease using bioluminescence, multiphoton microscopy, nanotechnology and optoacoustic technology for detection and treatment.

Innovative imaging and therapeutic strategies developed by the industry and selected for their potential to enhance detection and eradicate minimal residual disease will be tested in preclinical models for subsequent clinical evaluation.


The Department of Urology of the University of Bern is renowned world wide for its expertise in the treatment of urological cancers. The department has
a strong link between clinical and basic research in prostate cancer.

Prof. Dr. George Thalmann


The Institute of Applied Physics of the University of Berne is specialised in the generation and detection of electro-magnetic radiation and its interaction with matter. Research and development of laser systems and application methods for medicine are the main tasks of the department of biomedical photonics.
Prof. Dr. Martin Frenz

The Academic Urology Unit of the University of Sheffield has a vast experience in large scale clinical trials in prostate cancer, translational research (biomarkers), mechanisms of progression in prostate cancer.
Dr. Colby Eaton

The Department of Urology of the Leiden University Medical Centre has been involved for a long time in clinical studies on prostate cancer metastatic to the skeleton. In close collaboration with the department of Endocrinology at LUMC, the Urology department has pioneered clinical studies aimed at the treatment of bone metastasis from prostate cancer with bisphosphonates (potent inhibitors of osteoclastic bone resorption).
Dr. Gabri van der Pluijm

The Clinical Unit - pathophysiology of osteoporosis (INSERM Lyon) has expertise in the management of urological malignancies, specifically early prostate cancer, and in the diagnosis and care of skeletal metastases. The research program on prostate cancer progression and metastasis is done within the INSERM unit directed by Philippe Clezardin which has a specific orientation on bone metastasis pathophysiology.
Dr. Marc Colombel

The Biochemical Cell Physiology Group of the DKFZ investigates pathomechanisms of proliferative processes. Historically, the focus was on protein phosphorylation and cell cycle entry projects providing a broad range of useful know-how in protein and nucleic acid biochemistry, cell and molecular biology and molecular genetics. For several years, the research concentrates on tumor-associated bone diseases: osteoporosis, bone pain, and bone metastasis with emphasis on prostate cancer.
Prof. Walter Pyerin



Fukuda Denshi is developing, producing and selling medical ultrasound systems since more than 30 years. Based in France with a R&D unit in Basle, Switzerland it distributes its systems all over the world for all medical applications (cardio-vascular, radiology, ob/gyn, urology). KONTRON has a long experience in the development and integration of signal processing algorithms into hardware and software, and in their combination with an appropriate user interface in commercially sellable ultrasound systems. KONTRON has also facilities for measuring transducer characteristics.
Dr. Dieter Schweizer

Berthold Technologies is a German medium-sized company that produces sensors, detection systems and instruments since 1949. The range of products sold worldwide includes systems for industrial process control and radiation protection, and bioanalytical instruments. For biomedical research the main current products are microplate readers, fluorometers, luminometers and bioluminescence/fluorescence imagers.
Dr. Manfred Hennecke

Med Discovery is a spin-off of the Urology Research Unit of the Vaudois University Hospital Center (CHUV) in Lausanne, Switzerland by 3 biologists and 3 urologists. Med Discovery is active in the discovery and development of highly specific protein drugs to treat urogenital cancers. In a short timeframe, Med Discovery has discovered two novel groups of therapeutic proteins from which one has been validated in vivo for the treatment of urogenital cancers. By combining biological drug discovery expertise with a strong in-house knowledge of the medical urology field, Med Discovery is uniquely positioned to develop novel drugs for urological cancers and other related solid tumours.
Dr. David Deperthes

tp21 GmbH is a managing company, specialised on the management of complex innovation or interdisciplinary R&D projects. tp21’s focus on an integrative approach. This approach considers all aspects of the technological value creation chain that are necessary to enable innovation.
tp21 supports companies in the take-up of new technologies also by activities and training related to IPR matters, innovation finance and socio-economic (health, ethics, gender, foresight) matters.
Dr. Petra Zalud